methyl N-(tert-butoxycarbonyl)-O-benzyltyrosinate | 907945-10-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-(tert-butoxycarbonyl)-O-benzyltyrosinate
• 英文别名: Methyl (S)-3-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate；methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylmethoxyphenyl)propanoate
• CAS: 907945-10-2
• 化学式: C₂₂H₂₇NO₅
• 分子量: 385.46
• InChiKey: QGWMIQPMNNKJMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl N-(tert-butoxycarbonyl)-O-benzyltyrosinate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 N-Boc-O-(苯甲基)-DL-酪氨酸
  参考文献：
  名称：

  Total synthesis of virgineone aglycone and stereochemical assignment of natural virgineone

  摘要：

  The first total synthesis of virgineone aglycone has been achieved employing the tandem O-acylationmigration reaction and the olefin cross-metathesis as key steps for fragment couplings. The left-hand segment of virgineone was also synthesized. The absolute configuration of the reported virgineone aglycone was determined to be (2S,7RS,26S) based on NMR analyses and the specific rotation values of the synthetic compounds. The absolute configuration of the natural virgineone was presumed to be (2S,7S,26S) based on NMR analyses of the synthetic virgineone aglycone. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.03.006
• 作为产物：
  描述：

  methyl 2-[(t-butoxycarbonyl)amino]-3-(4-hydroxyphenyl)propanoate 、 溴甲苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 methyl N-(tert-butoxycarbonyl)-O-benzyltyrosinate
  参考文献：
  名称：

  EP1849465

  摘要：

  公开号：

文献信息

• AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1849465A1

  公开（公告）日：2007-10-31

  The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof

  本发明提供了一种 GPR 受体功能调节剂，包括由式表示的化合物： [其中环A是任选取代的异环或杂环，P是键或间隔物，环D是任选取代的单环芳香环，可与5-7元环缩合，V是键或由式-CR14＝CR15-或-N＝CR16-代表的基团（其中R14、R15 和 R16 各代表一个氢原子或任选取代的烃基），Q 是键或间隔物，W 是羧基或生物等价于羧基的基团]或其盐或其原药
• CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS
  申请人：Hangzhou Dac Biotech Co., Ltd.

  公开号：EP3888691A1

  公开（公告）日：2021-10-06

  The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

  本发明涉及具有丙氧基、取代丙烯酰（丙烯酰）或二取代丙酰基团的连接体，以及使用这种连接体将化合物，特别是细胞毒剂与细胞结合分子连接。
• Targeting ligands
  申请人：Arrowhead Pharmaceuticals, Inc.

  公开号：US10294474B2

  公开（公告）日：2019-05-21

  Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.

  本文介绍的新型靶向配体可与化合物（如治疗性化合物）连接，有助于将化合物导向体内靶点。本文公开的靶向配体可用于将表达抑制性寡聚化合物（如 RNAi 制剂）靶向肝细胞，以调节基因表达。本文公开的靶向配体与治疗化合物连接后可用于多种应用，包括治疗、诊断、靶点验证和基因组发现应用。包括本文公开的靶向配体的组合物与表达抑制性低聚化合物连接时，能够介导肝细胞（如肝细胞）中靶核酸序列的表达，这可能有助于治疗对细胞、组织或生物体中基因表达或活性的抑制有反应的疾病或病症。
• Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
  申请人：HANGZHOU DAC BIOTECH CO, LTD

  公开号：US11129910B2

  公开（公告）日：2021-09-28

  The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

  本发明涉及含有 2，3-二取代琥珀酸基团，或 2-单取代，或 2，3-二取代富马酸或马来酸（反式（E）-或顺式（Z）-丁二酸）基团、或乙炔二羧基，通过桥连接细胞结合分子上的硫醇对，将细胞毒剂和/或每个连接体上的一个或多个不同的功能分子与细胞结合分子共轭。本发明还涉及制造这种连接体的方法、使用这种连接体制造均相共轭物的方法，以及应用这种共轭物治疗癌症、感染和自身免疫性疾病的方法。
• DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE
  申请人：PFIZER INC.

  公开号：EP0828754B1

  公开（公告）日：2005-02-02